(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid
• 化学式: C60H125N15O25S
• 分子量: 1488.8
• InChiKey: RDEIXVOBVLKYNT-VQBXQJRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -11.55
• 重原子数：
  101
• 可旋转键数：
  19
• 环数：
  9.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  710
• 氢给体数：
  26
• 氢受体数：
  40

反应信息

• 作为反应物：
  描述：

  (2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-(aminomethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2R,3R,4R,5R)-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,6S)-3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid 以 水 为溶剂， 反应 228.0h， 生成 庆大霉素C1五乙酸酯盐
  参考文献：
  名称：

  Method for making solvent dilution microcarriers

  摘要：

  本申请公开了一种制备被命名为溶剂稀释微载体（SDMCs）的包封乘客分子的车辆的方法及其产品，该方法允许在通过溶解两性亲和性双层形成材料、适当的溶剂和乘客分子、加入水溶液和进一步加入溶剂形成的货架稳定的成型溶液后，立即或延迟形成包封车辆。通过将成型溶液稀释成水系、气溶胶化或在原位重水化，可以从成型溶液中组织SDMCs。

  公开号：

  US05269979A1

文献信息

• Covalently bonded high refractive index particle reagents and their use
  申请人：E. I. Du Pont de Nemours and Company

  公开号：US04401765A1

  公开（公告）日：1983-08-30

  Novel particle reagent for light scattering immunoassays are provided. The particle reagents are high refractive index shell-core polymers covalently bonded to compounds of biological interest. A method of measuring unknown concentrations of these compounds of biological interest by measuring changes in turbidity caused by particle agglutination or its inhibition is also provided.

  提供了一种用于光散射免疫分析的新型粒子试剂。这些粒子试剂是高折射率的壳-核聚合物，与生物感兴趣的化合物共价结合。还提供了一种通过测量由粒子凝聚或其抑制引起的浑浊度变化来测量这些生物感兴趣化合物的未知浓度的方法。
• Pharmaceutical preparation, method for its production as well as its use
  申请人：Heraeus Kulzer GmbH & Co. KG

  公开号：US20040067253A1

  公开（公告）日：2004-04-08

  The invention relates to hardly soluble antiphlogistic salts and antiphlogistic-antibiotic pharmaceutical preparations and their use. The hardly water soluble antiphlogistic antibiotics salts have as their cationic component one of the antibiotics gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicyline, oxytetracycline and rolitetracycline and as their anionic component one of the antiphlogistics ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and triamcinolone-21-sulfate. The antiphlogistic antibiotics salts are used in pharmaceutical preparations as controlled-release antibiotic/antibiotics drugs. The invention describes antiphlogistic-antibiotic pharmaceutical preparations for which mixtures in the solid state of aggregation are used, which are composed of an easily water soluble salt of gentamicin, clindamycin, neomycin, streptomycin, tetracycline, doxicycline, oxytetracycline and/or rolitetracycline and at least one easily water soluble salt of ibuprofen, naproxen, indomethacin, dexamethasone-21-phosphate, dexamethasone-21-sulfate, triamcinolone-21-phosphate and/or triamcinolone-21-sulfate and at least one inorganic and/or organic pharmaceutical adjuvant and which are used as permanent or temporary implants in the form of tablets and/or molded bodies.

  本发明涉及难溶性抗炎盐和抗炎抗生素制剂及其使用。难水溶性抗炎抗生素盐的阳离子组分为庆大霉素、林可霉素、新霉素、链霉素、四环素、多西环素、氧四环素和罗利四环素之一，阴离子组分为布洛芬、萘普生、消炎症、地塞米松-21-磷酸酯、地塞米松-21-硫酸酯、曲安奈德-21-磷酸酯和曲安奈德-21-硫酸酯之一。抗炎抗生素盐用作控制释放抗生素药物的制剂。本发明还描述了抗炎抗生素制剂，其中使用固态混合物，该混合物由庆大霉素、林可霉素、新霉素、链霉素、四环素、多西环素、氧四环素和/或罗利四环素的易水溶性盐和布洛芬、萘普生、消炎症、地塞米松-21-磷酸酯、地塞米松-21-硫酸酯、曲安奈德-21-磷酸酯和/或曲安奈德-21-硫酸酯的至少一个易水溶性盐和至少一个无机和/或有机制药助剂组成，并用作以片剂和/或成型体形式的永久或临时植入物。
• Dressing material having adsorbed thereon a solvent dilution
  申请人：Fountain Pharmaceuticals, Inc.

  公开号：US05133965A1

  公开（公告）日：1992-07-28

  A method for forming vehicles for encapsulating passenger molecules which have been named solvent dilution microcarriers (SDMCs), and the products of this process, are disclosed which allows for immediate or delayed formation of the encapsulating vehicles following creation of a shelf-stable formed solution by dissolution of amphipathic bilayer-forming materials, appropriate solvent, and the passenger molecule, addition of aqueous solution, and further addition of solvent. The SDMCs are organized from the formed solution by dilution into an aqueous system, aerosolization, or rehydration in situ. A dressing material is formed by adsorbing said shelf-stable formed solution onto said material.

  本发明公开了一种制备用于封装已命名为溶剂稀释微载体（SDMCs）的乘客分子的车辆的方法，以及该过程的产品。该方法允许在通过溶解两性两层体形成材料、适当的溶剂和乘客分子、加入水溶液以及进一步加入溶剂创建一种货架稳定的形成溶液后立即或延迟形成封装车辆。通过将形成的溶液稀释到水系中、气溶胶化或原位再水化，可以从形成的溶液中组织SDMCs。通过将所述货架稳定的形成溶液吸附到所述材料上，形成一种敷料材料。
• Sustained release of antifectives
  申请人：Boni Lawrence

  公开号：US20060073198A1

  公开（公告）日：2006-04-06

  Provided are lipid antiinfective formulations substantially free of anionic lipids with a lipid to antiinfective ratio is about 1:1 to about 4:1, and a mean average diameter of less than about 1 μm. Also provided is a method of preparing a lipid antiinfective formulation comprising an infusion process. Also provided are lipid antiinfective formulations wherein the lipid to drug ratio is about 1:1 or less, about 0.75:1 or less, or about 0.50:1 or less prepared by an in line fusion process. The present invention also relates to a method of treating a patient with a pulmonary infection comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention. The present invention also relates to a method of treating a patient for cystic fibrosis comprising administering to the patient a therapeutically effective amount of a lipid antiinfective formulation of the present invention.

  提供的是脂质抗感染制剂，其含有的阴离子脂质含量极低，脂质与抗感染剂的比例约为1:1至4:1，平均直径小于约1微米。还提供了一种制备脂质抗感染制剂的方法，包括输注过程。此外，还提供了脂质抗感染制剂，其中脂质与药物的比例约为1:1或更低，约为0.75:1或更低，或约为0.50:1或更低，通过在线熔合过程制备。本发明还涉及一种治疗肺部感染的方法，包括向患者施用本发明的脂质抗感染制剂的治疗有效量。本发明还涉及一种治疗囊性纤维化患者的方法，包括向患者施用本发明的脂质抗感染制剂的治疗有效量。
• Large-scale manufacturing process for the production of pharmaceutical compositions
  申请人：Banach Maria

  公开号：US20060073173A1

  公开（公告）日：2006-04-06

  Methods for manufacturing pharmaceutical compositions with a predetermined surface tension or other properties are provided. Also provided are pharmaceutical compositions with a predetermined surface tension or other properties, articles of manufacture containing the pharmaceutical compositions and systems for preparation of the compositions.

  提供了制造具有预定表面张力或其他性质的制药组合物的方法。还提供了具有预定表面张力或其他性质的制药组合物，包含制药组合物的制品以及制备组合物的系统。